Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)

NCT00773734 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

352

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis
Plaque-type Psoriasis

Interventions

DRUG: Apremilast 10mg
DRUG: Apremilast 20mg
DRUG: Apremilast 30 mg
DRUG: Placebo
DRUG: Apremilast 30mg
DRUG: Apremilast 20mg

Sponsor

Amgen